Investment Rating - The report maintains a "Buy" rating for the company with a target price of 7.02 CNY based on a 13x PE ratio for 2025 [2][5]. Core Insights - The company achieved a revenue of 151.81 billion CNY in 2024, reflecting a year-on-year growth of 1.1%. The net profit attributable to the parent company was 2.51 billion CNY, up 15.3% year-on-year [10]. - In Q1 2025, the company reported a revenue of 42.02 billion CNY, a 3.8% increase year-on-year, and a net profit of 970 million CNY, which is an 80.4% increase year-on-year [10]. - The CSO business showed strong competitiveness, with a revenue of 19.27 billion CNY in 2024, while the pharmaceutical industrial business grew by 21.5% to 3.01 billion CNY [10]. - The company is expanding its retail and new medical strategies, with over 29,000 franchise stores and a revenue of 5.39 billion CNY from franchise sales in 2024, marking a 54.9% increase [10]. Financial Summary - The company's projected financials for 2025 include: - Revenue: 162.73 billion CNY, a 7.2% increase year-on-year - Net profit: 2.70 billion CNY, a 7.7% increase year-on-year - Earnings per share: 0.54 CNY [3][12]. - The gross margin is expected to stabilize at 7.8% for 2025, with a net margin of 1.7% [3][12]. - The company’s total assets are projected to reach 103.29 billion CNY by 2025, with a debt-to-asset ratio of 66.1% [12].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 7.02 CNY based on a 13x PE ratio for 2025 [2][5]. Core Insights - The company achieved a revenue of 151.81 billion CNY in 2024, reflecting a year-on-year growth of 1.1%. The net profit attributable to the parent company was 2.51 billion CNY, up 15.3% year-on-year [10]. - The first quarter of 2025 saw a revenue of 42.02 billion CNY, a 3.8% increase year-on-year, and a net profit of 970 million CNY, which is an 80.4% increase year-on-year [10]. - The CSO business showed strong competitiveness, with a revenue of 19.27 billion CNY in 2024, while the pharmaceutical industrial business grew by 21.5% to 3.01 billion CNY [10]. - The company is expanding its retail and new medical strategies, with over 29,000 franchise stores and a revenue of 5.39 billion CNY from franchise sales, marking a 54.9% increase year-on-year [10]. Financial Summary - The company's projected financials for 2025 include: - Revenue: 162.73 billion CNY, a 7.2% increase from 2024 - Net profit: 2.70 billion CNY, a 7.7% increase from 2024 - Earnings per share: 0.54 CNY [3][12]. - The gross margin is expected to stabilize at 7.8% for 2025, with a net margin of 1.7% [3][12]. - The company’s market capitalization is approximately 26.57 billion CNY, with a PE ratio of 9.8 for 2025 [5][12].

证券代码：600998 证券简称：九州通 公告编号：临 2025-037 九州通医药集团股份有限公司 关于股东会开设网络投票提示服务的公告 若广大投资者对本次服务有任何意见或建议，可通过邮件、投资者热线等方 式向上证信息或公司反馈，感谢广大投资者对公司的关注与支持！ 特此公告。 九州通医药集团股份有限公司董事会 2025年5月22日 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 九州通医药集团股份有限公司（以下简称"公司"）已于 2025 年 4 月 29 日 披露《九州通关于召开 2024 年年度股东会的通知》（公告编号：2025-028）， 公司将于 2025 年 5 月 23 日 10：00 召开 2024 年年度股东会，本次会议采用现场 投票和网络投票相结合的表决方式。 为更好地服务广大中小投资者，确保有投票意愿的中小投资者能够及时参 会、及时投票，公司拟使用上证所信息网络有限公司（以下简称"上证信息"） 提供的股东会提醒服务，委托上证信息通过智能短信等形式，根据股权登记日的 股东名册主动提醒股东参会投票，向每一 ...

Core Viewpoint - 九州通 is actively expanding its strategic investments in the pharmaceutical and healthcare sectors, particularly focusing on medical aesthetics and medical devices through various initiatives and partnerships [1][2][3]. Investment Initiatives - 九州通's wholly-owned subsidiary, 九州通孵化器, has partnered with 北京楚昌私募基金 to establish a new investment fund with a total contribution of 25 million yuan, targeting investments in pharmaceuticals, medical devices, medical aesthetics, and anti-aging sectors [2][3]. - The fund's contributions include 22.99 million yuan from 九州通孵化器, accounting for 91.96% of the total, while the remaining contributions come from other partners [2]. Medical Device Expansion - 九州通 has established a new medical device supply chain company in 湖北孝感 with a registered capital of 10 million yuan, further diversifying its business operations [3]. - In the past three months, 九州通 has launched at least six new medical device companies, indicating a strong commitment to expanding its presence in the medical device sector [3]. - The medical device segment accounted for 22.32% of 九州通's total business last year, with sales revenue reaching 33.887 billion yuan in 2024, reflecting a year-on-year growth of 3.26% [3]. Medical Aesthetics Investment - 九州通 plans to invest 673 million yuan in the restructuring of 奥园美谷, acquiring 360 million shares post-restructuring, which positions the company to become a major stakeholder in the medical aesthetics market [4][6]. - 奥园美谷 has faced financial difficulties but possesses a recognized brand and customer base in the medical aesthetics sector, which 九州通 aims to leverage for growth [4]. - 九州通's medical aesthetics business achieved sales revenue of 851 million yuan in 2024, marking a significant year-on-year increase of 120.47% [4][6]. Historical Context - 九州通 has a history of investing in the medical aesthetics sector, including an early investment in 爱美客 and partnerships with other key players in the industry [5][6]. - The establishment of a dedicated medical aesthetics division and collaboration with upstream manufacturers for product development further underscores 九州通's commitment to this sector [6].

以下文章来源于睿兽Pro ，作者Bestla 睿兽Pro . 创业邦旗下横跨一二级市场的科创数据平台。实时投资数据、追踪产业创新。找数据、做分析、链资 源，就上睿兽分析。 上周基金重点事件回顾丨 05.12-05.18 睿兽分析每周整理最值得关注的 基金重点事件 ，帮助大家及时了解全球私募股权基金市场动向。 政府引导基金 湖州发布300亿产业母基金 近日，2025湖州未来大会开幕。会上，发布了总规模300亿元的湖州市产业母基金和全市首批15个 应用场景、25个场景项目；各区县作了投资环境视频推介；106个项目集中签约，总投资691.2亿 元，涵盖新能源汽车及关键零部件、半导体及光电、生物医药、高端装备等制造业，以及人才、科 技、现代服务业及农业等领域。据介绍，湖州市产业母基金总规模300亿元，采用"子基金+直投"模 式。直投模式强化链主引领，重点支持总投资10亿元以上重大引领性项目落地，重点投向新能源汽车 及关键零部件、半导体及光电、人工智能、高端装备、低空经济、生物医药等领域。子基金模式支持 投早、投小、投硬科技、投重大科创平台，子基金设立数量达30只。 （ 湖州发布） 安徽120亿元新能源环保基金选定第五 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The retail pharmacy sector has passed its low point and is gradually entering an industry consolidation phase, with performance recovery underway. The pressure on small and medium-sized pharmacies is increasing, leading to a rise in concentration among leading enterprises, supported by potential growth from policy recovery [4][10] - The pharmaceutical distribution market is expanding, and industry concentration is expected to increase, with a focus on improving the operational quality of leading companies. The implementation of the two-invoice system is shortening the drug distribution chain, benefiting leading enterprises with upstream and downstream resource advantages [4][10] Summary by Sections Retail Pharmacies - The number of retail pharmacies in China showed negative growth in Q4 2024, marking a turning point as the industry enters a "market consolidation phase." The number of closed pharmacies in 2024 was 6,778 in Q1, 8,791 in Q2, 9,545 in Q3, and 14,114 in Q4, with net additions of 9,257, 6,322, 2,847, and -3,395 respectively [10][11] - The performance of retail pharmacies is expected to stabilize and recover due to improved compliance operations and refined management practices, alongside seasonal disease outbreaks and new pricing policies [4][11] - Policies supporting the inclusion of retail pharmacies in outpatient management are expected to enhance their role in the healthcare system, facilitating prescription flow and increasing foot traffic to physical pharmacies [4][10][11] Pharmaceutical Distribution - The pharmaceutical distribution market is expected to grow, with leading companies benefiting from scale and operational quality improvements. The "4+N" competitive landscape is deepening, and the market size is expanding due to increased shares of retail pharmacies and grassroots medical terminals [4][10] - The use of AI technology and CSO services is expected to enhance the competitive edge of leading companies, reinforcing the trend of "the strong getting stronger" [4][10] Recommended and Beneficiary Stocks - Recommended stocks include Yifeng Pharmacy, Lao Bai Xing, and Jian Zhi Jia, while beneficiary stocks include Da Shen Lin, Yi Xin Tang, and Shu Yu Ping Min [4][15]

Overview - The article discusses the establishment of an industrial fund by a wholly-owned subsidiary of Jiuzhoutong Pharmaceutical Group in collaboration with professional investment institutions, which constitutes a related party transaction [1][2]. Fund Establishment and Related Transactions - The industrial fund, named Beijing Zhihui Jiuzhou Venture Capital Partnership, has a total subscribed capital of 25 million RMB, with Jiuzhoutong Incubator contributing 22.99 million RMB, representing 91.96% of the total [1][3]. - The investment aims to enhance the company's strategic layout in the pharmaceutical and technology sectors, focusing on areas such as pharmaceuticals, medical devices, and anti-aging [1][8]. Related Party Transaction Details - The investment constitutes a related party transaction as Chuchang Private Fund is a subsidiary of the company's controlling shareholder, Chuchang Investment Group, but does not qualify as a major asset restructuring [2]. - In the past 12 months, the company has engaged in related party transactions with Chuchang Private Fund totaling 336.54 million RMB [2]. Investment Partners - The general partner of the fund is Beijing Chuchang Private Fund Management Co., Ltd., while other limited partners include Jiuzhoutong Incubator and Ms. Xie Jiafang [3][4]. Fund Operations and Management - The fund will primarily focus on early-stage incubation projects in the pharmaceutical and technology sectors, with a planned investment period of 5 years and an optional extension of 2 years [4][5]. Financial Impact - The investment will be funded by the company's own resources and is not expected to adversely affect the company's operational activities or financial performance [8]. - The establishment of the fund is anticipated to enhance the company's core competitiveness in products, technology, and services by leveraging the advantages of the incubator and the capital provided by the fund [8]. Regulatory Compliance - The sponsor, CITIC Securities, has confirmed that the transaction complies with relevant regulations and does not require board or shareholder approval [8].

中信证券股份有限公司关于九州通医药集团股份有限公司 全资孙公司与专业投资机构共同投资设立产业基金暨关联 交易的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为九州通 医药集团股份有限公司（以下简称"公司"、"上市公司"或"九州通"）向特 定对象发行优先股的保荐人，根据《证券发行上市保荐业务管理办法》《上海证 券交易所股票上市规则》《上海证券交易所上市公司自律监管指引第 1 号——规 范运作》以及《上海证券交易所上市公司自律监管指引第 11 号——持续督导》 等相关规定，对九州通全资孙公司与专业投资机构共同投资设立产业基金暨关联 交易事项发表核查意见，具体情况如下： 一、设立产业基金及关联交易概述 （一）本次设立产业基金基本情况 为进一步促进公司旗下产业孵化器发展，进一步强化公司在医药大健康、科 技领域的战略布局，公司全资孙公司九州通孵化器于近日和楚昌私募基金、谢家 芳签署《北京智汇九州创业投资合伙企业（有限合伙）之有限合伙协议》（以下 简称"本协议"），各方共同投资设立智汇九州创投，投资于药品、医疗器械、 医美、抗衰等领域。该合伙企业的认缴出资额为 2,500 万元，其中九州通孵化器 作 ...

证券代码：600998 证券简称：九州通 公告编号：临 2025-035 九州通医药集团股份有限公司 关于全资孙公司与专业投资机构共同投资设立 产业基金暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 为进一步促进公司旗下产业孵化器发展，加大公司在医药大健康、科技领域 的战略布局，九州通医药集团股份有限公司（简称"九州通"或"公司"）全资 孙公司北京九州通科技孵化器有限公司（以下简称"九州通孵化器"）作为有 限合伙人认缴出资2,299万元，与北京楚昌私募基金管理有限公司（以下简称 "楚昌私募基金"）共同投资设立北京智汇九州创业投资合伙企业（有限合伙） （以下简称"智汇九州创投"、"合伙企业"或"产业基金"）。 楚昌私募基金为公司控股股东楚昌投资集团有限公司的下属控股企业，故本 次共同投资构成关联交易，但不构成重大资产重组；本次交易事项无需提交 公司董事会和股东会审议。 截至本公告披露日，过去12个月内，公司与楚昌私募基金发生关联交易的合 计金额为33,653.78万元（已分别经董事会或股东会审议 ...

证券代码：600998 证券简称：九州通 公告编号：临 2025-036 九州通医药集团股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 被担保人名称及是否为上市公司关联人：被担保人包括上海九州通医药有限 公司、浙江九州通医药有限公司等 44 家子公司（含河南九州通医药有限公司、 江苏九州通医药有限公司等 22 家全资子公司），不存在关联担保； ● 本次担保金额及已实际提供的担保余额：九州通医药集团股份有限公司（以 下简称"公司"或"九州通集团"）4 月新增担保金额合计 41.55 亿元，同时解 除担保金额合计 30.15 亿元。2025 年经批准的公司及下属企业向银行等金融机 构和其他机构办理综合授信及其他业务的总额不超过 736.57 亿元，截至 2025 年 4 月 30 日，公司实际提供担保余额为 277.24 亿元，主要为对控股子公司（含 全资子公司）及其下属企业的担保，公司拥有被担保方的控制权，且其现有经 营状况良好，因此担保风险可控； ● 本次担保是 ...